[go: up one dir, main page]

IL143841A0 - Amide compounds and pharmaceutical compositions containing the same - Google Patents

Amide compounds and pharmaceutical compositions containing the same

Info

Publication number
IL143841A0
IL143841A0 IL14384100A IL14384100A IL143841A0 IL 143841 A0 IL143841 A0 IL 143841A0 IL 14384100 A IL14384100 A IL 14384100A IL 14384100 A IL14384100 A IL 14384100A IL 143841 A0 IL143841 A0 IL 143841A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
amide compounds
amide
Prior art date
Application number
IL14384100A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of IL143841A0 publication Critical patent/IL143841A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14384100A 1999-01-14 2000-01-06 Amide compounds and pharmaceutical compositions containing the same IL143841A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds
PCT/JP2000/000017 WO2000042011A1 (en) 1999-01-14 2000-01-06 Amide compounds

Publications (1)

Publication Number Publication Date
IL143841A0 true IL143841A0 (en) 2002-04-21

Family

ID=3812385

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14384100A IL143841A0 (en) 1999-01-14 2000-01-06 Amide compounds and pharmaceutical compositions containing the same
IL143841A IL143841A (en) 1999-01-14 2001-06-19 Amid compounds, processes for their preparation, and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143841A IL143841A (en) 1999-01-14 2001-06-19 Amid compounds, processes for their preparation, and pharmaceutical preparations containing them

Country Status (21)

Country Link
US (2) US6710043B1 (es)
EP (1) EP1140836B1 (es)
JP (2) JP3617454B2 (es)
KR (2) KR100520406B1 (es)
CN (1) CN1142910C (es)
AR (1) AR028812A1 (es)
AT (1) ATE502923T1 (es)
AU (1) AUPP818099A0 (es)
BR (1) BRPI0008753B8 (es)
CA (1) CA2360360C (es)
CZ (1) CZ20012562A3 (es)
DE (1) DE60045759D1 (es)
ES (1) ES2363492T3 (es)
HK (1) HK1044337B (es)
HU (1) HU230422B1 (es)
IL (2) IL143841A0 (es)
RU (1) RU2208608C2 (es)
TR (1) TR200102038T2 (es)
TW (1) TWI229075B (es)
WO (1) WO2000042011A1 (es)
ZA (1) ZA200104713B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
JPWO2002045715A1 (ja) * 2000-12-07 2004-04-08 藤沢薬品工業株式会社 抗痴呆効果増強剤
US7812035B2 (en) * 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
NZ540111A (en) * 2002-12-06 2008-04-30 Dow Agrosciences Llc Synergistic fungicidal compositions
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1814875A4 (en) 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE
JP2008519078A (ja) * 2004-11-04 2008-06-05 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのアリールアルキル尿素類
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
JP2010507587A (ja) * 2006-10-20 2010-03-11 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
TW200825072A (en) * 2006-10-20 2008-06-16 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
EP2157082B1 (en) 2007-04-20 2016-06-08 Senju Pharmaceutical Co., Ltd. Neurite formation promoter
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
WO2009071509A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (es) 1969-06-30 1974-10-28
US3647805A (en) 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (es) 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
DE2860314D1 (en) 1977-11-24 1981-02-19 Synthelabo Derivatives of naphthalene, process for their preparation and their therapeutic application
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
DK397387A (da) 1986-07-31 1988-02-01 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf samt fremgangsmaade til fremstilling af saadanne forbindelser
CA1322199C (en) 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
DE69430861T2 (de) * 1993-04-07 2003-01-23 Otsuka Pharmaceutical Co., Ltd. N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
JP3489116B2 (ja) * 1993-06-18 2004-01-19 藤沢薬品工業株式会社 新規合成中間体およびアミノピペラジン誘導体の製造法
US5500423A (en) 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
IL117805A0 (en) * 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
GB9519077D0 (en) 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
WO1997017957A1 (en) 1995-11-13 1997-05-22 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
US6284760B1 (en) * 1996-12-24 2001-09-04 Fujisawa Pharmaceutical Co., Ltd. Method of treating schizophrenia, depression and other neurological conditions
EP0968201A2 (en) * 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
KR100520406B1 (ko) 2005-10-11
CA2360360A1 (en) 2000-07-20
ZA200104713B (en) 2002-09-09
US20040014745A1 (en) 2004-01-22
CN1142910C (zh) 2004-03-24
BRPI0008753B8 (pt) 2021-05-25
AR028812A1 (es) 2003-05-28
HUP0105108A3 (en) 2002-11-28
ES2363492T3 (es) 2011-08-05
CN1336917A (zh) 2002-02-20
EP1140836A1 (en) 2001-10-10
JP2004002414A (ja) 2004-01-08
HUP0105108A2 (hu) 2002-05-29
HU230422B1 (hu) 2016-05-30
TWI229075B (en) 2005-03-11
WO2000042011A1 (en) 2000-07-20
BR0008753B1 (pt) 2013-11-12
US6710043B1 (en) 2004-03-23
RU2208608C2 (ru) 2003-07-20
HK1044337B (zh) 2004-11-26
EP1140836B1 (en) 2011-03-23
IL143841A (en) 2006-07-05
KR20010093819A (ko) 2001-10-29
AUPP818099A0 (en) 1999-02-11
ATE502923T1 (de) 2011-04-15
KR20040063001A (ko) 2004-07-09
CA2360360C (en) 2009-09-08
BR0008753A (pt) 2001-11-06
CZ20012562A3 (cs) 2001-11-14
JP3617454B2 (ja) 2005-02-02
DE60045759D1 (de) 2011-05-05
JP2002534503A (ja) 2002-10-15
KR100525809B1 (ko) 2005-11-03
HK1044337A1 (en) 2002-10-18
TR200102038T2 (tr) 2002-01-21

Similar Documents

Publication Publication Date Title
IL143841A0 (en) Amide compounds and pharmaceutical compositions containing the same
IL138573A0 (en) Amide derivatives and pharmaceutical compositions containing the same
IL148517A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL150077A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL144910A0 (en) Cyclic compounds and pharmaceutical compositions containing the same
IL139479A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL149883A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
IL150224A0 (en) Lipopeptides and pharmaceutical compositions containing the same
IL144977A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
HUP0103256A3 (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
IL150223A0 (en) Lipopeptides and pharmaceutical compositions containing the same
IL138899A0 (en) Amidene derivatives and pharmaceutical compositions containing the same
HUP0202254A3 (en) Amide substituted imidazoquinolines and pharmaceutical compositions containing them
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL148489A0 (en) Quinazoline compounds and pharmaceutical compositions containing them
IL144879A0 (en) Hererocyclic biphenyl compounds and pharmaceutical compositions containing the same
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL151829A0 (en) Carbamate derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed